Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Estrogen receptor alpha

5

Estrogen receptor beta

5

Estrogen-related receptor alpha

5

Estrogen-related receptor beta

5

Estrogen-related receptor gamma

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1941

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Amenorrhea

5

Atrophic vaginitis

5

Female hypogonadism

5

Menopausal syndrome

5

Miscarriage

5

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

5

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Dodds E.C. et al.

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

ECHA (EC/EINECS)

5

FDA UNII

5

MERCK INDEX

5

PUBCHEM

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

2

GENITO URINARY SYSTEM AND SEX HORMONES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ENDOCRINE THERAPY

2

SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

HORMONES AND RELATED AGENTS

2

ESTROGENS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Estrogens

2

Estrogens, combinations with other drugs

1

Synthetic estrogens, plain

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

FOSFESTROL

A0E0NMA80F

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1941

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

estrogen receptor 1

estrogen receptor 2 (ER beta)

estrogen-related receptor alpha

estrogen-related receptor beta

estrogen-related receptor gamma

Estrogen receptor alpha

Estrogen-related receptor gamma

Estrogen receptor beta

Estrogen-related receptor alpha

Estrogen-related receptor beta

Conditions:

Prostate cancer

Prostate cancer

Atrophic vaginitis

Vulvar dystrophy

Female hypogonadism

Postmenopausal osteoporosis

Menopausal syndrome

Diethylstilbestrol is a synthetic non-steroidal estrogen. It is used in the treatment of menopausal and postmenopausal disorders, prostate cancer and in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or pre...

mature delivery. Diethylstilbestrol is a very potent full agonist of the estrogen receptors. At the cellular level, estrogens increase the synthesis of DNA, RNA, and various proteins in target tissues. Pituitary mass is also increased. Estrogens reduce the release of gonadotropin-releasing hormone from the hypothalamus, leading to a reduction in release of follicle-stimulating hormone and luteinizing hormone from the pituitary. Adverse effects are: breast pain or tenderness, enlargement of breasts, gynecomastia, peripheral edema and others. Estrogens may interfere with the effects of bromocriptine. Dosage adjustment may be needed. Concurrent use with estrogens may alter the metabolism and protein binding of the glucocorticoids, leading to decreased clearance, increased elimination half-life, and increased therapeutic and toxic effects of the glucocorticoids.

FOSFESTROL DISODIUM

961Q1V15RZ

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1941

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

estrogen receptor 1

estrogen receptor 2 (ER beta)

estrogen-related receptor alpha

estrogen-related receptor beta

estrogen-related receptor gamma

Estrogen receptor alpha

Estrogen-related receptor gamma

Estrogen receptor beta

Estrogen-related receptor alpha

Estrogen-related receptor beta

Conditions:

Prostate cancer

Prostate cancer

Atrophic vaginitis

Vulvar dystrophy

Female hypogonadism

Postmenopausal osteoporosis

Menopausal syndrome

Diethylstilbestrol is a synthetic non-steroidal estrogen. It is used in the treatment of menopausal and postmenopausal disorders, prostate cancer and in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or pre...

mature delivery. Diethylstilbestrol is a very potent full agonist of the estrogen receptors. At the cellular level, estrogens increase the synthesis of DNA, RNA, and various proteins in target tissues. Pituitary mass is also increased. Estrogens reduce the release of gonadotropin-releasing hormone from the hypothalamus, leading to a reduction in release of follicle-stimulating hormone and luteinizing hormone from the pituitary. Adverse effects are: breast pain or tenderness, enlargement of breasts, gynecomastia, peripheral edema and others. Estrogens may interfere with the effects of bromocriptine. Dosage adjustment may be needed. Concurrent use with estrogens may alter the metabolism and protein binding of the glucocorticoids, leading to decreased clearance, increased elimination half-life, and increased therapeutic and toxic effects of the glucocorticoids.

FOSFESTROL SODIUM

G9I1882VSD

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1941

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

estrogen receptor 1

estrogen receptor 2 (ER beta)

estrogen-related receptor alpha

estrogen-related receptor beta

estrogen-related receptor gamma

Estrogen receptor alpha

Estrogen-related receptor gamma

Estrogen receptor beta

Estrogen-related receptor alpha

Estrogen-related receptor beta

Conditions:

Prostate cancer

Prostate cancer

Atrophic vaginitis

Vulvar dystrophy

Female hypogonadism

Postmenopausal osteoporosis

Menopausal syndrome

Diethylstilbestrol is a synthetic non-steroidal estrogen. It is used in the treatment of menopausal and postmenopausal disorders, prostate cancer and in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or pre...

mature delivery. Diethylstilbestrol is a very potent full agonist of the estrogen receptors. At the cellular level, estrogens increase the synthesis of DNA, RNA, and various proteins in target tissues. Pituitary mass is also increased. Estrogens reduce the release of gonadotropin-releasing hormone from the hypothalamus, leading to a reduction in release of follicle-stimulating hormone and luteinizing hormone from the pituitary. Adverse effects are: breast pain or tenderness, enlargement of breasts, gynecomastia, peripheral edema and others. Estrogens may interfere with the effects of bromocriptine. Dosage adjustment may be needed. Concurrent use with estrogens may alter the metabolism and protein binding of the glucocorticoids, leading to decreased clearance, increased elimination half-life, and increased therapeutic and toxic effects of the glucocorticoids.

DIETHYLSTILBESTROL

731DCA35BT

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1941

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

estrogen receptor 1

estrogen receptor 2 (ER beta)

estrogen-related receptor alpha

estrogen-related receptor beta

estrogen-related receptor gamma

Estrogen receptor alpha

Estrogen-related receptor gamma

Estrogen receptor beta

Estrogen-related receptor alpha

Estrogen-related receptor beta

Conditions:

Prostate cancer

Prostate cancer

Atrophic vaginitis

Vulvar dystrophy

Female hypogonadism

Postmenopausal osteoporosis

Menopausal syndrome

Diethylstilbestrol is a synthetic non-steroidal estrogen. It is used in the treatment of menopausal and postmenopausal disorders, prostate cancer and in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or pre...

mature delivery. Diethylstilbestrol is a very potent full agonist of the estrogen receptors. At the cellular level, estrogens increase the synthesis of DNA, RNA, and various proteins in target tissues. Pituitary mass is also increased. Estrogens reduce the release of gonadotropin-releasing hormone from the hypothalamus, leading to a reduction in release of follicle-stimulating hormone and luteinizing hormone from the pituitary. Adverse effects are: breast pain or tenderness, enlargement of breasts, gynecomastia, peripheral edema and others. Estrogens may interfere with the effects of bromocriptine. Dosage adjustment may be needed. Concurrent use with estrogens may alter the metabolism and protein binding of the glucocorticoids, leading to decreased clearance, increased elimination half-life, and increased therapeutic and toxic effects of the glucocorticoids.

DIETHYLSTILBESTROL DIPROPIONATE

Y98CK3J0OL

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1941

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

estrogen receptor 1

estrogen receptor 2 (ER beta)

estrogen-related receptor alpha

estrogen-related receptor beta

estrogen-related receptor gamma

Estrogen receptor alpha

Estrogen-related receptor gamma

Estrogen receptor beta

Estrogen-related receptor alpha

Estrogen-related receptor beta

Conditions:

Prostate cancer

Prostate cancer

Atrophic vaginitis

Vulvar dystrophy

Female hypogonadism

Postmenopausal osteoporosis

Menopausal syndrome

Diethylstilbestrol is a synthetic non-steroidal estrogen. It is used in the treatment of menopausal and postmenopausal disorders, prostate cancer and in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or pre...

mature delivery. Diethylstilbestrol is a very potent full agonist of the estrogen receptors. At the cellular level, estrogens increase the synthesis of DNA, RNA, and various proteins in target tissues. Pituitary mass is also increased. Estrogens reduce the release of gonadotropin-releasing hormone from the hypothalamus, leading to a reduction in release of follicle-stimulating hormone and luteinizing hormone from the pituitary. Adverse effects are: breast pain or tenderness, enlargement of breasts, gynecomastia, peripheral edema and others. Estrogens may interfere with the effects of bromocriptine. Dosage adjustment may be needed. Concurrent use with estrogens may alter the metabolism and protein binding of the glucocorticoids, leading to decreased clearance, increased elimination half-life, and increased therapeutic and toxic effects of the glucocorticoids.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1